Gitnux/Report 2026

Nootropics Industry Statistics

The global nootropics market is estimated at $6.37 billion in 2026, explore the figures behind its 2026–2034 growth, company focus, and the evidence and regulatory signals shaping product choices.
28Statistics
14Sources
5Sections
1Visuals
14mRead
November 20, 2026Updated
Nootropics Industry Statistics
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The nootropics industry at a glance

The global nootropics market is estimated at $6.37 billion in 2026 and is forecast to reach $12.85 billion by 2034, with North America holding 38.74% of 2025 revenue.

$6.37B[4]
Global market size, 2026
9.17%[4]
Forecast CAGR, 2026–2034
38.74%[4]
North America share, 2025
$1.23B[9]
Cognitive supplement sales, 2026
Market size
The global nootropics market was valued at $5.86 billion in 2025 and is estimated at $6.37 billion in 2026. A separate estimate places the 2025 market at $5.2 billion, reflecting differences in market scope and methodology.[4][2]
Forecast & CAGR
Fortune Business Insights forecasts growth from $6.37 billion in 2026 to $12.85 billion in 2034 at a 9.17% CAGR. Grand View Research projects a higher 12.7% CAGR from 2026 to 2033, reaching $13.3 billion.[4][2]
Market share & regions
North America was the largest regional market in 2025, accounting for 38.74% of global revenue and $2.27 billion in sales. Asia-Pacific is identified as a fast-growing region and is estimated to reach $1.66 billion in 2026.[4]
Segmentation
Natural nootropics accounted for 67.61% of 2025 revenue, while capsules and tablets held 41.76%. Memory enhancement represented 27.41% of 2025 market value, and online retail accounted for 34.23%.[3]
Key players & concentration
The market is described as low-concentration, with major participants including Onnit Labs, Reckitt Benckiser, Mind Lab Pro, TruBrain, Nootropics Depot, Amway and Natural Stacks. Public sources reviewed did not provide a verified combined market share for the leading companies.[3][2]
Trends, drivers & challenges
Cognitive-health supplement sales reached $1.23 billion and grew 3.5% year over year, while unit sales increased 4.9%. Growth is being supported by interest in focus, memory, stress and sleep products, but evidence quality, product transparency and regulatory scrutiny remain challenges.[9][8]
Consumer behavior & competition
A 2025 U.S. survey found that 19% of consumers listed mental clarity and focus among their top supplement goals. Euromonitor reported that 69% of consumer-health product launches and reformulations featured cognitive claims during 2021–2025, indicating competition is extending beyond dedicated nootropic supplements into beverages, foods and other wellness products.[10][11]
M&A
Unilever agreed to acquire Onnit in 2021 and completed the acquisition on May 28, 2021. The transaction terms were not disclosed in the cited company and regulatory filings.[12][13]
Regulation
In the United States, nootropic supplements marketed as dietary supplements are governed primarily by the 1994 Dietary Supplement Health and Education Act. FDA generally does not approve supplement claims or labeling before sale; manufacturers must submit notifications for certain new dietary ingredients and products remain subject to post-market enforcement.[8]
Latest news
The latest industry reporting shows cognitive-health supplement sales at $1.23 billion, up 3.5% year over year, with creatine products carrying cognitive-support claims up 77.6% to $627.4 million. Euromonitor also reported $2.66 billion in 2025 retail sales for memory-related claims.[9][11]

02 Ranking

Top 2 Companies in the Nootropics Industry

The leading companies in the nootropics industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Qualia Life Sciences stands out for its nootropic product line because its nootropic products launched in 2015, while Nootropics Depot focuses on nootropic ingredients and formats since it is listed among key companies in the U.S. nootropics market.

Ranked by Overall score · How we score ↓

Full ranking

Sort by
Top 2 companies in the nootropics industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Qualia Life Sciences

Nootropic supplements retail · US

8.7
2

Nootropics Depot

Nootropic supplements retail · US

8.5

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Timothy Grant. (2026, February 13). Top 2 companies in the nootropics industry. In Nootropics Industry Statistics. Gitnux. https://gitnux.org/nootropics-industry-statistics/#top-companies

report visual · Comparison

Global nootropics market revenue by target audience

Working Professionals holds the largest share at $2.8B.

Working Professionals$2.8B
Students and Academics$2.7B
Athletes$2.0B
Aging Population$749.5M
Others$367.1M
source-verifiedstatifacts.com

04 Statistics

Market Intelligence

Market sizing points to a $6.37B global estimate in 2026, with North America at 38.74% of 2025 revenue. The forecast extends to $12.85B by 2034 at a 9.17% CAGR.

Market size, volume and shipments in the nootropics industry

  • USD 5.19 billion was the global nootropics market value in 2025, covering natural, synthetic, prescription and over-the-counter nootropics.[1]
  • USD 5.2 billion was the global nootropics market value in 2025, covering capsules/tablets, powders, drinks and other forms across online and offline channels.[2]
  • USD 4.91 billion was the global nootropics market value in 2025, based on Mordor Intelligence’s proprietary market-estimation framework.[3]
  • USD 5.86 billion was the global nootropics market value in 2025, covering synthetic, natural/herbal and other nootropics across formulations and distribution channels.[4]

Forecast growth and shipments in the nootropics industry

  • The global nootropics market is projected to reach USD 9.89 billion by 2031, growing at a 12.37% CAGR from 2026 to 2031.[3]
  • The global nootropics market is projected to reach USD 12.85 billion by 2034, growing at a 9.17% CAGR from 2026 to 2034.[4]
  • The global nootropics market is projected to reach USD 16.64 billion by 2034, growing at a 13.82% CAGR from 2026 to 2034.[1]
  • The global nootropics market is projected to reach USD 13.3 billion by 2033, growing at a 12.7% CAGR from 2026 to 2033.[2]

Regional split of the nootropics industry

  • North America accounted for 38.74% of global nootropics market revenue in 2025 under Fortune Business Insights’ regional segmentation.[4]
  • North America accounted for 38.2% of global nootropics market revenue in 2025, equivalent to USD 1.98 billion.[1]
  • Asia-Pacific accounted for 23.1% of global nootropics market revenue in 2025, equivalent to USD 1.20 billion.[1]
  • North America accounted for 40.9% of global nootropics market revenue in 2025 under Grand View Research’s regional segmentation.[2]
  • Europe accounted for 27.4% of global nootropics market revenue in 2025, equivalent to USD 1.42 billion.[1]

05 Statistics

Product & Standards

Composition testing highlights detection patterns across 159 samples from 10 countries during January 2020–September 2024. Examples include 15% racetam-family molecules and 50.5% of detected molecules listed on packaging.

Materials, inputs and substitution in nootropics

  • 15% of tested nootropic samples contained racetam-family molecules, measured across 159 samples from 10 countries during January 2020–September 2024.[5]
  • 20% of tested nootropic samples contained acetylcholinesterase inhibitors, measured across 159 samples from 10 countries during January 2020–September 2024.[5]
  • 22% of tested nootropic samples contained central-nervous-system stimulants, measured across 159 samples from 10 countries during January 2020–September 2024.[5]

06 Statistics

Production & Operations

Operational compliance shows up in dosing and label alignment: the highest melatonin amount measured was 20.3 mg per capsule or tablet, and 5 of 21 melatonin samples exceeded 10 mg by at least 20%.

Defects and conformance in the nootropics industry

  • 50.5% of detected nootropic molecules were listed on product packaging, measured across 159 samples from 10 countries during January 2020–September 2024.[5]
  • 20.3 mg per capsule or tablet was the highest melatonin amount found in a tested nootropic supplement, measured during January 2020–September 2024.[5]
  • 5 of 21 melatonin-containing nootropic samples exceeded the recommended maximum daily amount of 10 mg by at least 20%, measured during January 2020–September 2024.[5]

07 Statistics

Customers & Channel

Channel data emphasizes online distribution, with 34.23% of global revenue from online retail in 2025. Function splits show memory enhancement at 27.41% of global market value and focus and concentration at 38.6%.

Distribution channels for nootropics

  • 48.8% of global nootropic-supplement revenue came through online retail in 2025, including brand-direct websites and third-party marketplaces; the study defines the category as nootropic supplements.[6]
  • 34.23% of global nootropics revenue came from online retail stores in 2025; the study covers capsules, tablets, powders, drinks and other nootropic formats.[3]
  • Online channels accounted for 28% of global nootropics revenue in 2024, with the category segmented into offline and online distribution.[7]

Demand by end use for nootropics

  • Focus and concentration accounted for 38.6% of global nootropic-supplement market value in 2025; the study defines applications as consumer use cases.[6]
  • Memory enhancement represented 27.41% of global nootropics market value in 2025; this is a value split by consumer-facing function, not a buyer adoption rate.[3]
  • Adults aged 18–44 accounted for 57.71% of global nootropics market value in 2025; this is a value split by end-user age group.[3]

08 Statistics

Regulation & Risk

Enforcement and testing signals remain active: four unlawful or undeclared stimulant-related ingredients were identified across two Addall products, and FDA issued an April 2026 enforcement advisory for two Addall dietary-supplement products.

Enforcement and penalties in the nootropics industry

  • Four unlawful or undeclared stimulant-related ingredients were identified across the two Addall products: phenibut, 1,4-DMAA, DMHA and 1,4-DMAA’s duplicate product occurrence.[8]
  • One permanent injunction was entered on June 2, 2023, against Chill6 for distributing phenibut-containing products marketed with disease-treatment claims.[8]
  • Two Addall dietary-supplement products were subject to FDA’s April 2026 enforcement advisory: one orange-flavored shot and one 30-capsule product marketed through retail and online channels.[8]

Key questions about the Nootropics Industry

What is the global nootropics market size in 2026?
The global nootropics market is estimated at $6.37 billion in 2026.
How fast is the nootropics market expected to grow after 2026?
Fortune Business Insights forecasts growth to $12.85 billion by 2034, at a 9.17% CAGR from 2026 to 2034.
Which companies lead the nootropics industry?
Qualia Life Sciences stands out for its nootropic product line because its nootropic products launched in 2015, while Nootropics Depot focuses on nootropic ingredients and formats since it is listed among key companies in the U.S. nootropics market.
What technology or product-form shifts are showing up in market data?
Capsules and tablets account for 41.76% of 2025 revenue, while online retail represents 34.23% of global nootropics revenue in 2025.
How is the market structured by region and channel?
North America held 38.74% of 2025 revenue, and 34.23% of 2025 global revenue came from online retail stores.
What evidence and compliance risks show up in product testing and enforcement?
In sample testing across 159 samples from 10 countries during January 2020–September 2024, 20% contained acetylcholinesterase inhibitors, and four unlawful or undeclared stimulant-related ingredients were identified across the two Addall products.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Timothy Grant. (2026, February 13). Nootropics Industry Statistics. Gitnux. https://gitnux.org/nootropics-industry-statistics
MLA
Timothy Grant. "Nootropics Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/nootropics-industry-statistics.
Chicago
Timothy Grant. 2026. "Nootropics Industry Statistics." Gitnux. https://gitnux.org/nootropics-industry-statistics.